What is Cagrilintide ?
Cagrilintide is a synthetic, long-acting acylated analogue of the human hormone amylin . Amylin is a peptide hormone that is co-secreted with insulin by the pancreatic beta-cells in response to food intake. It plays a crucial role in regulating post-meal blood glucose levels and appetite.
The key innovation behind Cagrilintide is its engineered stability. By being acylated, it gains a significantly prolonged duration of action in the body, making it suitable for once-weekly subcutaneous administration, similar to modern GLP-1 therapies . Its chemical structure features 38 amino acids and includes a disulfide bridge, which is critical for its stability and biological function .
Prat 1 :Mechanism of Action: Harnessing the Power of Amylin
Cagrilintide functions as a non-selective agonist for the amylin receptor (AMYR) and the calcitonin G protein-coupled receptor (CTR) . By mimicking the natural amylin hormone, it exerts its effects through several distinct pathways:
Reduction of Food Intake: It acts on the brain's satiety centers, specifically in the hypothalamus, to promote feelings of fullness and reduce appetite .
Slowing of Gastric Emptying: It delays the rate at which food leaves the stomach, leading to a more gradual absorption of nutrients into the bloodstream. This helps prevent sharp postprandial blood glucose spikes .
Inhibition of Glucagon Secretion: It suppresses the release of glucagon, a hormone that raises blood sugar levels, thereby contributing to better glycemic control .
This multi-faceted mechanism is complementary to that of GLP-1 receptor agonists, which primarily stimulate insulin secretion and also suppress appetite. This synergy is the scientific basis for investigating Cagrilintide in combination with semaglutide.
Part 2 :Clinical Evidence: Groundbreaking Results from Phase 3 Trials
The most robust data on Cagrilintide's efficacy comes from the recently published REDEFINE 1 and REDEFINE 2 phase 3 clinical trials.
REDEFINE 1: Obesity Without Type 2 Diabetes
This trial involved over 3,400 adults with obesity or overweight with comorbidities but without type 2 diabetes . After 68 weeks of treatment:
Cagrilintide + Semaglutide (CagriSema): Achieved a remarkable mean weight reduction of -20.4%.
Semaglutide alone (2.4 mg): Achieved a -14.9% reduction.
Cagrilintide alone (2.4 mg): Achieved a -11.5% reduction.
Placebo: Resulted in a -3.0% reduction.
The combination therapy (CagriSema) was significantly more effective than either drug alone, demonstrating a powerful synergistic effect. Furthermore, the combination also led to significant improvements in systolic and diastolic blood pressure, lipid levels, and physical function .
REDEFINE 2: Obesity With Type 2 Diabetes
This trial focused on over 1,200 adults with both type 2 diabetes and overweight or obesity . The results were equally impressive:
Cagrilintide + Semaglutide: Achieved a mean weight loss of -13.7%.
Placebo: Resulted in a -3.4% reduction.
Beyond weight loss, the combination therapy had a profound impact on glycemic control:
It reduced HbA1c (a key marker of long-term blood sugar) by -1.8%, compared to -0.4% with placebo.
Notably, 81% of patients achieved an HbA1c of ≤6.5%, and 39.2% even reached normoglycemia (HbA1c <5.7%) .
Continuous glucose monitoring (CGM) data showed patients spent 86.8% of their time in the target blood sugar range, indicating very stable glucose control .
Part 3 :The Future of Cagrilintide and CagriSema
The data from the REDEFINE trials position Cagrilintide, particularly in its fixed-dose combination CagriSema, as a potential best-in-class therapy. The dual-hormone approach targets multiple pathways involved in obesity and diabetes simultaneously, offering a highly effective treatment strategy.
The research community is optimistic that such combinations will allow for more personalized treatment algorithms, helping clinicians and patients find the most effective strategy based on individual health needs and treatment responses .
Conclusion: A Promising New Pillar in Metabolic Care
Cagrilintide is more than just another weight-loss drug; it is a pioneering therapy that revitalizes the amylin pathway with modern pharmaceutical engineering. Its significant efficacy in reducing body weight and improving glycemic parameters, both as a monotherapy and in combination with semaglutide, underscores its potential to become a fundamental tool in managing two of the most prevalent chronic diseases worldwide-obesity and type 2 diabetes.
As regulatory reviews and further studies progress, Cagrilintide (CagriSema) is poised to offer a new, powerful option for millions of patients seeking better health outcomes.
And Joy Biotech is the supplier of Cagrilintide , welcome to contact us for more information(eileen@joybiotech.com).

